Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Hypoxia-preconditioned adipose-derived stem cells with injectable small intestinal submucosa for enhanced cartilage repair in osteoarthritis.

Yu K., Ma L., Han P., Liu Y., Zou L., Wang S.

Laboratory Study on Osteoarthritis, Cartilage Damage, published in Bioeng Transl Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Bioeng Transl Med (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
42272955
PMCID
PMC13247430
DOI
10.1002/btm2.70116

Abstract (original English)

Osteoarthritis (OA) is a widespread degenerative condition marked by inflammation-induced damage to chondrocytes and gradual breakdown of the cartilage extracellular matrix. Adipose-derived mesenchymal stem cells (ADSCs) hold potential for treating OA due to their capacity to differentiate into various cell types and their paracrine signaling functions. However, the inflammatory environment in OA reduces ADSC viability post-injection, while the absence of a supportive carrier causes significant cell loss, impairing their capacity for cartilage repair. To address these challenges, we improved the stemness and paracrine activity of ADSCs through hypoxia preconditioning and integrated them into an injectable small intestinal submucosa (SIS) tissue repair scaffold. This resulted in an SIS + ADSC composite material, designed for intra-articular injection to enhance cartilage repair in arthritis. Our findings revealed that exposing ADSCs to 2% oxygen during hypoxia preconditioning and incorporating them into injectable SIS significantly increased the secretion of growth factors (VEGF, bFGF, EGF) and upregulated key hypoxia and stem cell markers (HIF-1α, NANOG, SOX-2, Oct-4). In a rat OA model, hypoxia-preconditioned SIS + ADSC composites markedly enhanced cartilage repair by stimulating anabolic activity, suppressing catabolic pathways, and reducing inflammation, thereby exhibiting s

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research